Skip to main content
;

CIIT Committee Report

If you have any questions or comments regarding the accessibility of this publication, please contact us at accessible@parl.gc.ca.

PDF

LIST OF RECOMMENDATIONS

 

As a result of their deliberations committees may make recommendations which they include in their reports for the consideration of the House of Commons or the Government. Recommendations related to this study are listed below.

Recommendation 1

That the Government of Canada, when implementing the proposed use of foreign decisions pathway, take actions designed to enhance the domestic competitiveness of Canadian biocides manufacturers. In this regard, the Government should identify and address existing challenges that negatively affect Canada’s biocides sector.

Recommendation 2

That the Government of Canada ensure that Health Canada has sufficient resources to assess, in a timely manner, applications for a market authorization to import biocides into Canada or to sell biocides domestically. In addition, to ensure that Canadian firms have sufficient time to meet all requirements after the proposed regulations are implemented, the Government should take two actions: provide Canadian firms with a one-year period within which to submit an application for market authorization to import or sell biocides while continuing to rely on their existing authorization; and, establish a moratorium regarding the proposed regulations, such that implementation would occur only after Health Canada has processed all of the applications submitted during that one-year period.

Recommendation 3

That the Government of Canada identify the most significant barriers to exports of Canadian biocides, including to the United States. The Government should then develop and implement a strategy to eliminate or reduce those barriers and to increase the value of these exports.

Recommendation 4

That the Government of Canada, on an expeditious basis, establish a working group that would identify regulatory gaps and propose solutions to those gaps with the goal of eliminating obstacles to achieving reciprocity with the country’s trading partners—particularly the United States—concerning the recognition of Health Canada’s decisions regarding market authorization for the domestic sale of biocides. This working group should include representatives from Canada’s biocides sectors, as well as other relevant stakeholders.